Sugi Predict

Sugi Predict / Compounds / SCHEMBL23950880

SCHEMBL23950880

SCHEMBL23950880

CC(C)(C)OC(=O)N1CC[C@H](N)C[C@H]1CCO

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.39
▸ NR1H2 P55055 1/20 0.38
▸ CHRM2 P08172 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ CHRM3 P20309 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.35
▸ PDE8B O95263 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38657326 0.89 NR1H2 (0.42) NR1H2CHRM2CHRM1CHRM3HSD17B10
SCHEMBL28823446 0.86 ATM (0.40) ATMCHRM2CHRM1CHRM3HSD17B10
SCHEMBL21748842 0.86 CHRM2 (0.39) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL13845953 0.86 CHRM2 (0.39) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL18434915 0.85 NR1H2 (0.35) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL3850660 0.85 ATM (0.46) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL5005297 0.85 ATM (0.46) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL7411944 0.85 ATM (0.46) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL10145373 0.84 ATM (0.39) ATMNR1H2CHRM2CHRM1CHRM3
SCHEMBL24876034 0.83 CHRM2 (0.37) ATMNR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030884-B2 Pyrazoloquinoline KRAS inhibitors INCYTE CORPORATION (US) 2024-07-09 — — US disclosed
US-20230143938-A1 PYRAZOLOQUINOLINE KRAS INHIBITORS INCYTE CORPORATION 2023-05-11 — — US disclosed
US-20230144051-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION 2023-05-11 — — US disclosed
EP-4135844-A1 FUSED TRICYCLIC KRAS INHIBITORS Incyte Corporation (US) 2023-02-22 — — EP disclosed
CN-115702025-A Fused tricyclic KRAS inhibitors 因赛特公司 2023-02-14 — — CN disclosed
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION 2021-11-18 — — US disclosed
WO-2021211864-A1 FUSED TRICYCLIC KRAS INHIBITORS INCYTE CORPORATION (US) 2021-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143938-A1 PYRAZOLOQUINOLINE KRAS INHIBITORS KRAS, NRAS, HRAS ATM 806/4885NR1H2 1187/4885CHRM2 4856/4885
US-20230144051-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS ATM 1240/4885NR1H2 882/4885CHRM2 4782/4885
US-12030884-B2 Pyrazoloquinoline KRAS inhibitors KRAS, NRAS, HRAS ATM 806/4885NR1H2 1187/4885CHRM2 4856/4885
US-20210355121-A1 FUSED TRICYCLIC KRAS INHIBITORS KRAS, NRAS, HRAS ATM 1407/4885NR1H2 1228/4885CHRM2 4875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.